Teva Pharmaceuticals @TevaUSA
There are many hurdles in biosimilar development, yet it’s critically important for the industry to forge ahead this critical category, says Teva’s Cory Wohlbach at #GRxBiosims. Biosimilars can help bring affordable medicines to patients and savings to the US healthcare system. https://t.co/THM4KT0uSP — PolitiTweet.org